Anders Rane

[Introduction of genetic analysis can provide us with safer doping tests. Large variation in androgen turnover creates problems in current tests].

Anders Rane, Lena Ekström, 2012, Lakartidningen.

SFINX—a drug-drug interaction database designed for clinical decision support systems

Tuomas Korhonen, Kari Laine, Lars L. Gustafsson, 2009, European Journal of Clinical Pharmacology.

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

Nicole Soranzo, Panos Deloukas, Fumihiko Takeuchi, 2009, PLoS genetics.

EXPRESSION OF CYP3A ISOFORMS AND P‐GLYCOPROTEIN IN HUMAN STOMACH, JEJUNUM AND ILEUM

Roberto Canaparo, Loredana Serpe, Anders Rane, 2007, Clinical and experimental pharmacology & physiology.

Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.

Yoshihide Hayashizaki, Mia Wadelius, Masahiko Kurabayashi, 2009, Clinical chemistry.

Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism.

Claes Ohlsson, Mattias Lorentzon, Anders Rane, 2006, The Journal of clinical endocrinology and metabolism.

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy

Munir Pirmohamed, Robert J Glynn, Stephen E Kimmel, 2011, Thrombosis and Haemostasis.

The largest prospective warfarin-treated cohort supports genetic forecasting.

Panos Deloukas, Niclas Eriksson, Mia Wadelius, 2009, Blood.

Internet based clinical trial protocols -- as applied to a study of warfarin pharmacogenetics.

Marius Kublickas, Anders Rane, J. Lindh, 2004, British journal of clinical pharmacology.